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Abstract  
 
Introduction: High-risk human papillomavirus (HPV) infection is one of the major 
causes of infection-related cancers worldwide. MicroRNAs (miRNAs) are a family of non-
coding RNAs (ncRNAs), whose function is to modulate the expression of genes involved in 
essential cellular processes, and which are dysregulated in many cancers. MiRNA-150 
expression profile in HPV-induced lesions remains elusive. K14-HPV16 transgenic mice 
express the early genes of HPV16 in basal keratinocytes, leading to the development of 
hyperplastic and dysplastic skin lesions and squamous cell carcinomas, thus becoming a 
representative model of HPV-induced cancers. Celecoxib is a cyclooxygenase-2 (COX-2) 
inhibitor and several studies have been confirming that this pharmacological agent is able 
to suppress tumor growth.  
Material and Methods: In order to evaluate the expression of miR-150 in HPV-
induced lesions, we performed qPCR to measure the miR-150 levels in wild-type mice 
(HPV-/-), in skin lesions of K14-HPV16 transgenic mice (HPV+/-) with no treatment and in 
skin lesions of HPV+/- mice treated with two doses of celecoxib. To assess the type of lesion 
present in each mouse, histological evaluation was also performed. 
Results: 24-26 weeks old HPV+/- mice showed epidermal hyperplasia and 
dysplasia, but HPV+/- mice at 28-30 weeks old presented higher incidence of dysplasia. 
MiR-150 was upregulated in lesions of HPV+/- mice when compared with normal skin from 
HPV-/- mice. MiR-150 was also overexpressed in lesions of HPV+/- mice at 28-30 weeks of 
age when compared with lesions of HPV+/- mice at 24-26 weeks of age. In lesions of HPV+/- 
mice treated with 124 mg/kg/day of celecoxib, miR-150 expression decreased significantly 
when compared with lesions of HPV+/- mice without treatment and the incidence of 
epidermal dysplasia was not observed. In HPV+/- mice treated with 75 mg/kg/day of 
celecoxib, statistical significance was not observed. 
Conclusions: The results obtained suggest that miR-150 is overexpressed in HPV-
induced lesions in this model and its expression seems to increase with lesions progression. 
Celecoxib may modulate the expression of miR-150 in HPV-induced lesions in a seemingly 
dose-dependent manner. Given the influence of miR-150 in the progression of HPV-induced 
lesions, further studies are needed. 
 
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Resumo 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Resumo 
21 
 
Resumo 
 
Introdução: A infeção por papilomavírus humano (HPV) de alto risco é uma das 
principais causas de cancro relacionado com infeções em todo o mundo. Os microRNAs 
(miRNAs) são uma família de RNAs não codificantes (ncRNAs), cuja função é modular a 
expressão de genes envolvidos em processos celulares essenciais, e cuja expressão se 
pode encontrar desregulada em vários cancros. O perfil de expressão do miRNA-150 em 
lesões induzidas por HPV ainda não é bem conhecido. Os murganhos transgénicos K14-
HPV16 expressam os genes da região early do HPV16 nos queratinócitos basais, o que 
leva ao desenvolvimento de lesões hiperplásicas e displásicas na pele e a carcinomas de 
células escamosas, tornando-se assim um modelo representativo de neoplasias 
associadas ao HPV. O celecoxib é um inibidor da ciclocoxigenase-2 (COX-2) e vários 
estudos têm confirmado que este fármaco é capaz de impedir o crescimento tumoral.  
Material e Métodos: Para realizar este estudo, foi usado qPCR para avaliar os 
níveis de expressão do miR-150 em murganhos do tipo selvagem (HPV-/-), em lesões de 
murganhos transgénicos K14-HPV16 (HPV+/-) sem tratamento e em lesões de murganhos 
HPV+/- tratados com baixa e alta dose de celecoxib. Para determinar o tipo de lesão 
presente em cada murganho foi realizada a análise histológica de cada amostra.  
Resultados: Em murganhos HPV+/- com 24-26 semanas de idade foram 
observadas lesões hiperplásicas e displásicas, mas os murganhos HPV+/- com 28-30 
semanas apresentam maior incidência de displasia. Em lesões de murganhos HPV+/- 
verificou-se um aumento da expressão do miR-150 em comparação com murganhos HPV-
/-. O MiR-150 também se encontra sobreexpresso em lesões de murganhos HPV+/- com 28-
30 semanas de idade quando comparado com lesões de murganhos HPV+/- com 24-26 
semanas de idade. Em lesões de murganhos HPV+/- tratados com 124 mg/kg/dia de 
celecoxib, a expressão do miR-150 diminuiu significativamente quando comparado com 
lesões de murganhos HPV+/- sem tratamento e a incidência de displasia não foi observada. 
Em murganhos HPV+/- tratados com 75 mg/kg/day de celecoxib não foram encontradas 
diferenças estatisticamente significativas. 
Conclusão: Os resultados obtidos sugerem que neste modelo o miR-150 é 
sobreexpresso em lesões induzidas pelo HPV e que a sua expressão parece aumentar 
com a progressão das lesões. O celecoxib parece modular a expressão do miR-150 em 
lesões provocadas pelo HPV de um modo dependente da dose. Dada a influência do miR-
150 na progressão das lesões induzidas pelo HPV, estudos futuros são necessários. 
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Introduction 
 
1. Cancer  
1.1. Definition and Epidemiology  
Cancer is a group of diseases characterized by genetic and/or epigenetic changes 
that alter the expression or function of key genes responsible for regulating fundamental 
cellular processes [1,2]. The dysregulation of the different cellular signaling pathways 
results in the formation of abnormal cells with an uncontrolled growth and capable of 
invading tissues and metastasize to distant sites [1,2].  
Cancer has revealed itself as a growing public health problem worldwide. The 
incidence of cancer is increasing and it is the leading cause of death worldwide due to 
population growth and ageing as well as increasing prevalence of risk factors such as 
smoking, obesity, physical inactivity and changing of reproductive patterns [3]. According to 
GLOBOCAN, in 2012 an estimated 14.1 million new cases of cancer and 8.2 million deaths 
occurred worldwide [3]. In Portugal, over 24 000 deaths due to oncologic diseases were 
observed in 2012 [4]. For the next decades, an increase of 38% is expected in the overall 
number of deaths in Portuguese population, with a higher increase in men than in women 
[4]. 
 
1.2. Biology 
The process that leads a normal tissue to transform into a neoplastic tissue is called 
tumorigenesis, which is a multistep process that requires the accumulation of successive 
alterations that confer selective advantage to the neoplastic cell (also known as hallmarks 
of cancer) [5,6]. These hallmarks include sustaining proliferative signaling, evading growth 
suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, 
and activating invasion and metastasis [5,6]. Due to advances in cancer research, additional 
hallmarks have emerged such as capability to modify or reprogram cellular metabolism, 
capacity to evade immunological destruction in particular by T and B lymphocytes, 
macrophages and natural killer cells, genomic instability and tumor-promoting inflammation 
[6].  
The majority of genetic and epigenetic changes that give rise to these hallmarks 
necessary for tumorigenesis are not inherited, but arise spontaneously as a consequence 
of DNA damage by chemical, physical or biological carcinogens [7].  
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Nowadays, the biological carcinogens are a well characterized group which includes 
infectious agents such as a few helminths (Clonorchis sinensis, Opisthorchis viverrini and 
Schistosoma haematobium), bacteria (Helicobacter pylori) and some viruses [8,9]. 
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2. Tumor Viruses 
The virus-tumor association was established in the middle 20th century, with the 
identification of some viruses as strong risk factors for specific cancers [10]. It is estimated 
that 15%-20% of human cancers worldwide are attributable to viral infection and the majority 
occurs in less developed regions [9,11–13].  
The first evidence that viruses can cause cancer came in 1908, when it was shown 
by Vilhelm Ellermann and Olaf Bang that a cell-free filtrate of chicken leukemia cells could 
transmit leukemia when inoculated into healthy chickens. However, leukemia was not 
considered as a neoplastic disease until the 1930s, therefore the filterable agent present in 
the leukemia cell extracts was not recognized as a tumor virus and the importance of this 
discovery went largely unnoticed [14]. A few years later, in 1911, Peyton Rous showed that 
a cell-free filtrate from spindle cell sarcoma derived from a chicken could transmit the 
disease to healthy chickens, indicating that the tumor was due to a filterable agent, later 
known as Rous sarcoma virus (RSV) (Figure 1) [14,15]. Thereby, this discovery, awarded 
with the Noble Prize in Physiology or Medicine in 1966, led to the recognition of a new 
paradigm in cancer research: the virus-induced cancer [13,14]. 
 
 
Figure 1 - Peyton Rous’ protocol for inducing sarcomas in chickens. Adapted from [16]. 
 
Viruses can contribute to carcinogenesis by direct and/or indirect mechanisms [17]. 
In direct carcinogenesis, the virus induces expression of oncogenes causing a tumor 
phenotype in the infected cell [17]. In indirect carcinogenesis, the virus is not conditioned to 
exist within the cell that forms the tumor and acts through chronic inflammation that 
persistently damage the surrounding tissues, or by inducing immunosuppression which 
reduces or eliminates immune surveillance [17]. 
Since the first evidences of virus-induced cancer, diverse molecular, epidemiologic 
and serologic studies have uncovered the carcinogenic potential of further viruses [11]. Up 
to now, viruses that are proven to be associated with human cancer are listed in Table 1. 
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Table 1 - Human Tumor Viruses 
Virus Human Cancers 
Carcinogenic 
mechanism 
References 
High-risk Human 
Papillomavirus (HPV) 
Cervical, Head and 
neck, Vagina, Vulva, 
Anus, Penis 
Direct carcinogenesis [9,13,18] 
Epstein-Barr Virus 
(EBV) 
Burkitt’s lymphoma, 
Nasopharyngeal 
carcinoma, Hodgkin 
lymphoma, Gastric 
carcinoma 
Direct carcinogenesis [9,13,19] 
Human T-cell 
lymphotropic virus type 
1 (HTLV-1) 
Adult T-cell leukemia 
Indirect carcinogenesis 
via immune 
suppression 
[9,13,20] 
Kaposi’s Sarcoma-
Associated Herpesvirus 
(KSHV) / Human 
Herpes Virus 8 (HHV-
8) 
Kaposi sarcoma, 
Primary effusion 
lymphoma 
Direct carcinogenesis [9,13,21] 
Hepatitis B Virus (HBV) 
Hepatocellular 
carcinoma 
Direct carcinogenesis or 
indirect carcinogenesis 
via chronic 
inflammation 
[9,13,17] 
Hepatitis C Virus (HCV) 
Hepatocellular 
carcinoma, Non-
Hodgkin lymphoma 
Direct carcinogenesis or 
indirect carcinogenesis 
via chronic 
inflammation 
[9,13,17] 
 
Currently, one of the best established etiological agent of human cancer is the 
Human papillomavirus (HPV). Epidemiological studies implicated high-risk HPV infection as 
one of the major causes of infection-related cancers worldwide and particularly as the main 
cause of cervical cancer. Cervical cancer is the second leading cause of cancer-related 
mortality in women worldwide, with approximately 85% of these deaths occurring in 
developing countries (Figure 2) [22–24].  
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Figure 2 - Estimated cervical cancer mortality worldwide in 2012. Estimated age-
standardised rate per 100,000. Adapted from: GLOBOCAN (http://globocan.iarc.fr/). 
 
Finally, and most importantly, bearing in mind the impact of these agents in the 
development of cancer, the discovery and study of these viruses and its carcinogenic 
mechanisms is extremely important for prevention, prognostic and treatment of virus-
induced cancers [11,13,17]. 
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3. Human Papillomavirus  
Papillomaviruses (PVs) are non-enveloped, double-stranded DNA (dsDNA) and 
icosahedral-shaped viruses with 50–60 nm of diameter, that belong to the family 
Papillomaviridae [25–27]. This group infects not only mammals but also birds and reptiles 
[28].  
In humans, more than 150 HPV types have been identified, that are contained within 
five evolutionary groups with different epithelial tropisms and life cycle strategies: Alpha-
papillomavirus, Beta-papillomavirus, Gamma-papillomavirus, Mu-papillomavirus and Nu-
papillomavirus (Figure 3) [27,28]. The Beta and Gamma HPV types cause chronic  
unapparent infections and produce virions without causing apparent damage to the host 
[28]. On the other hand, the Alpha-papillomavirus includes the low-risk types associated 
with genital warts, and the high-risk types that are associated with the development of 
certain types of cancer [28].  
 
 
Figure 3 - Evolutionary Relationship between the five HPV groups. Adapted from [27]. 
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The association between high-risk HPV and cancer was discovered by Harald zur 
Hausen in 1974, through the detection of HPV DNA in cervical cancer and genital wart 
biopsies, which gave him the Noble Prize in Physiology or Medicine in 2008 [29]. 
Currently, it is recognized that approximately 5% of all cancers worldwide are 
attributed to high-risk HPVs, according them the classification of group 1 human 
carcinogens by the International Agency for Research on Cancer (IARC) [18]. The infection 
by HPV is commonly transmitted by sexual contact and affects men and women [30,31]. 
The World Health Organization (WHO) defined thirteen high-risk types of HPV (16, 18, 3, 
33, 35, 39, 45, 51, 52, 56, 58, 59 and 68) which are considered as the causal agents for 
cancers of the uterine cervix, vagina, vulva, anus, penis and some head and neck cancers 
[18,28].  
The most prevalent high-risk HPV type in the worldwide population is HPV16 
followed by HPV18 [24]. Moreover, in cervical cancer HPV DNA is present at least in 99,9% 
of the cases, being that HPV16 is present in more than 50% and HPV18 in approximately 
15% [18,25]. In head and neck squamous cell carcinomas, HPV16 is found in up to 90% of 
HPV-positive cases [32].  
HPV16 has the typical genome organization of the high-risk Alpha-papillomaviruses 
(Figure 4) [28]. Its genome contains around 8000 base pairs that comprise a long control 
region (LCR) and eight open reading frames (ORFs) (E6, E7, E1, E2, E4, E5, L1 and L2) 
that are necessary for the different stages of the virus life cycle [28,30,33].  
Specifically, the LCR contains binding sites for cellular transcription factors as well 
as for E1 and E2 proteins [28]. The coding sequences have been classified as early (E) 
containing the early genes (E6, E7, E1, E2, E4 and E5) and late (L) containing the late 
genes namely the L1 and L2 genes [28].  
The early genes are responsible for the regulation of the viral replication: E1 function 
as the regulator of episomal viral DNA replication; E2 is a transcriptional regulator of E6 and 
E7; E4 is involved in cytoskeletal reorganization; E5 stimulates cell growth and E6 and E7 
are the transforming proteins [30,33]. Conversely, the late genes encode the viral capsid 
proteins for packaging newly synthesized virions [33]. Moreover, PAE indicates the position 
of the early polyadenylation site and PAL indicates the position of the late polyadenylation 
site, while PE (or p97) and PL (or p670) represent the early and late promoter, respectively 
(Figure 4) [28].  
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Figure 4 - dsDNA genome organization of HPV16. Adapted from [28]. 
 
3.1. HPV Life Cycle  
HPV is a non-lytic virus that infects the stratified squamous epithelium and the 
completion of its life cycle depends on epithelial squamous differentiation [26,34]. In fact, 
the regulation of viral gene expression occurs while the infected basal cell migrates towards 
the epithelial surface (Figure 5) [34].  
 
Figure 5 - HPV life cycle. Adapted from [30]. 
 
Initial infection requires the presence of microlesions in the epithelium that allow the 
infectious virions to access the epithelial basal stem cells, which are the only actively 
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dividing cells in the epithelial layer [27,28,32,34]. Additionally, active cell division due to 
wound healing is necessary for viral genome entry into the cell nucleus [27]. Once in these 
basal cells, the viral genome is maintained as a low copy number episome (often quoted as 
200 copies per cell) [27]. However, while the infected cells divide, viral DNA is distributed 
between both daughter cells: one daughter cell continues to divide in the basal layer and 
the other migrates away from the basal layer and initiates cell differentiation. Therefore, 
HPV DNA replicates to a high copy number only in terminally differentiated cells near the 
epithelial surface [32,35].  
In the mid or upper epithelial layers occurs the amplification of the viral genome and 
its package into infectious particles [34]. Since terminally differentiated epithelial cells are 
normally unable to support DNA synthesis, E6 and E7 proteins play an essential role in 
driving S-phase re-entry to allow viral genome amplification [27,32]. Finally, the completion 
of the HPV life cycle involves expression of two structural proteins: the major coat protein 
(L1) and minor coat protein (L2) which will allow the genome packaging [27,34].  
 
3.2. HPV-induced Carcinogenesis  
In the absence of the control of HPV infection by immunological intervention, lesions 
caused by high-risk HPV may persist and in some instances progress to cancer through a 
multistep process that develops from premalignant intraepithelial hyperplastic and 
dysplastic lesions to carcinoma in situ (CIS), and subsequently to invasive squamous cell 
carcinoma (Figure 6) [30,34,36].  
 
Figure 6 – Stages of cancer development. Adapted from: National Cancer Institute 
(http://www.cancer.gov) 
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In high-risk HPV, E6 and E7 proteins play an oncogenic role due to their capacity to 
form specific complexes with tumor suppressor proteins inducing proliferation, 
immortalization and malignant transformation in the basal and parabasal cell layers [27,37]. 
The tumor suppressor p53 is one of the targets of E6 oncoprotein [38]. p53 is a DNA-
binding protein expressed in response to DNA damage or unscheduled induction of DNA 
replication, resulting in cell cycle arrest or apoptosis [37]. Particularly, E6 binds to p53 
protein through a cellular ubiquitin-ligase, the E6-associated protein (E6-AP), which recruits 
the ubiquitin complex initiating p53 proteolysis [37]. Degradation of p53 causes 
chromosomal instability (with mutational consequences), inactivation of Bax (a pro-
apoptotic Bcl-2 protein) and enhancement of foreign DNA integration into the host-cell 
genome [37,39]. Moreover, E6 can also upregulate telomerase activity by the activation of 
the catalytic subunit of human telomerase (hTERT) [37,38]. Telomerase is an enzyme that 
replicates telomeric DNA at the ends of chromosomes and whose activity is absent in 
normal somatic cells. Thus, when telomeres get shorter through successive cell divisions, 
it is initiated the natural pathway that leads to senescence and cell death [37]. However, the 
upregulation of telomerase activity by E6 oncoprotein allows cell immortalization and long-
term tumor growth [40]. Additionally, E6 inhibits degradation of SRC-family kinases by E6-
AP, stimulating mitotic activity (Figure 7) [37].  
On the other hand, E7 oncoprotein is an inactivator of the retinoblastoma protein 
(pRB) [38]. In normal cells, the active form of pRB is hypophosphorylated and bound to E2F 
transcription factors [37]. This complex recruits chromatin remodeling factors (histone 
deacetylases (HDACs) and histone methyltransferases (HMTs)) and inhibits the 
transcription of genes required for the S-phase [1]. Therefore, cells remain in G1 phase of 
cell cycle [1]. Upon phosphorylation, pRB becomes inactive and dissociates from E2F 
allowing it to act as a transcriptional activator of S-phase genes leading to cell cycle 
progression [1,37]. When E7 oncoprotein is associated with hypophosphorylated pRB, the 
formation of the pRB/E2F complex is inhibited, and E2F promotes the cell cycle progression 
[37]. E7 also interacts with p170 and p130, two other members of the pRb family, whose 
function is also to downregulate E2F transcription [37]. It is also reported that E7 stimulates 
the S-phase genes cyclin E and cyclin A, interacts with cyclin-kinase complexes and annuls 
the inhibitory activities of cyclin-dependent kinase inhibitors (CKIs), such as p21CIP-1/WAF-1 
and p27KIP-1 [37]. In addition, E7 can induce genomic instability by inducing centriole 
amplification (Figure 7) [37]. Furthermore, E7 reduces the total major histocompatibility 
complex (MHC) abundance at the cell surface, which is expected to contribute to immune 
escape [27]. 
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Figure 7 - Cellular interactions of E6 and E7 oncoproteins for induction of cell 
immortalization. Adapted from [37]. 
 
In addition to E6 and E7, the papillomaviral E5 proteins have been shown to 
contribute to tumor progression through the stimulation of cell growth by forming a complex 
with the epidermal growth-factor receptor (EGFR), the platelet-derived growth factor-β 
receptor (PDGFβR) and the colony-stimulating factor-1 receptor (CSF-1R) [30]. Likewise, it 
is reported that E5 prevents apoptosis following DNA damage and also contributes to 
immune escape by interfering with the classical MHC class I process, compromising the 
display of viral peptides at the surface of the infected epithelial cell [27,30]. 
For 40 years, diverse biological and epidemiological studies have been 
demonstrating the association of cervical cancer and persistent HPV infection. However, it 
is important to highlight that although high-risk HPV infection is necessary and the main 
driver of cervical carcinogenesis, it is not sufficient to complete the neoplastic transformation 
[18]. In fact, recent studies have significantly enhanced the complexity of HPV-induced 
carcinogenesis with the discovery of non-coding RNAs (ncRNAs) as important players at 
regulating a variety of pathways involving proliferation, differentiation and immune 
surveillance [41,42].  
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4. MicroRNAs 
For normal cells, it is crucial that protein synthesis occurs in a controlled manner 
[43]. Therefore, the expression of a gene may be regulated at the genetic and/or epigenetic 
level [43]. The epigenetic regulation comprises three fields: DNA methylation, histone 
modifications and expression of ncRNAs [43]. NcRNAs comprehend different classes of 
RNAs that do not encode a protein, in which are included the microRNAs (miRNAs), a well-
conserved family of approximately 22 nucleotides in length [44,45]. 
In 1993, the first miRNA, lin-4, was identified in the nematode Caenorhabditis 
elegans during developmental timing studies. Since then, remarkable advances in the 
characterization of miRNAs have demonstrated that these molecules are a prevalent class 
of regulatory RNAs, whose function is to modulate gene expression [45,46]. 
Numerous studies have indicated that miRNAs play a role in most of the 
fundamental biological processes such as development, proliferation, apoptosis, 
hematopoietic lineage differentiation and tumorigenesis [45,47–49]. Moreover, it is 
estimated that miRNAs control 30%-90% of the human and mouse transcriptome [50]. 
Actually, miRNA expression and regulation are dynamic processes, and it is postulated that 
each miRNA regulates approximately 100 different messenger RNAs (mRNAs) and that 
more than 10.000 mRNAs appear to be directly regulated by miRNAs [51]. 
MiRNAs biogenesis initiates in the nucleus, passes through many post-
transcriptional modifications and ends in the cytoplasm (Figure 8) [45]. MiRNAs genes are 
mostly transcribed by RNA polymerase II, generating primary-miRNAs (pri-miRNAs) with a 
hairpin RNA structure [45]. These pri-miRNAs are processed by the microprocessor which 
is composed by enzymes Drosha (a RNase III endonuclease) and DiGeorge syndrome 
critical region gene 8 (DGCR8, a double-stranded RNA-binding protein also known as 
Pasha), into approximately 70-nucleotide precursor-miRNAs (pre-miRNAs) [45,52]. 
Specifically, the RNase domains of Drosha cleave the 5’ and 3’ arms of the pri-miRNAs and 
DGCR8 directly and stably interacts with the pri-miRNAs and determines the precise 
cleavage site [53].  
After nuclear processing, pre-miRNAs are exported to the cytoplasm via Exportin-5 
(XPO5) in complex with Ran-GTP [53]. In the cytoplasm, the RNase III Dicer in association 
with the double-stranded RNA-binding protein (TRBP) processes pre-miRNAs into their 
mature form by excising a double-stranded RNA of approximately 22 nucleotides in length 
(miRNA:miRNA* duplex) from the pre-miRNA hairpin [52,53]. Only the strand with a 
relatively lower stability of base-pairing at the 5’-end of the miRNA:miRNA* duplex is loaded 
together with Argonaute (AGO) proteins into the miRNA-induced silencing complex 
(miRISC), that guides the single-stranded miRNAs to their target mRNAs [53,54].  
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The function of miRNAs is to negatively regulate gene expression by post-
transcriptional mechanisms [52]. The 5’-end region (also known as ‘seed site’) of the miRNA 
is important for the stability and correct loading of the miRNA into the miRISC complex and 
for binding to the target mRNA [52,55]. MiRNAs mainly recognize the 3’-untranslated region 
(UTR) in their target mRNAs, but recent studies have reported that miRNAs can also bind 
to the ORF or the 5’-UTR [55]. When a miRNA binds to its target mRNA with imperfect 
complementarity  translational repression is induced [52]. Conversely, miRNAs that bind to 
their target mRNA with perfect or nearly perfect complementarity induce target mRNA 
cleavage (Figure 8) [52].  
 
 
 
Figure 8 - MiRNAs biogenesis and function. Adapted from [52]. 
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4.1. MicroRNAs and Cancer 
More than 50% of miRNA genes are located in cancer-associated genomic regions 
or in fragile sites which suggests that miRNAs may play an important role in cancer 
pathogenesis [56].  
The first evidence that miRNAs are involved in cancer emerged in 2002 when Calin, 
G.A. et al. found that miR-15a and miR-16–1 are downregulated or deleted in most patients 
with B-cell chronic lymphocytic leukemia [57]. Since then, several studies have emerged 
concerning the role of miRNAs in neoplastic diseases [57–60].  
One of the most important features of miRNAs is that they show abnormal 
expression in cancerous cells in relation to normal tissues. These expression changes may 
occur as consequence of chromosomal abnormalities, mutations, single nucleotide 
polymorphisms (SNPs), epigenetic changes and defects in the miRNA biogenesis 
machinery (Figure 9) [57,58,60]. Furthermore, dysregulated miRNAs expression is tumor-
specific and in some cases associated with diagnostic, prognostic and response to 
treatment [58]. 
 
 
Figure 9 - Causes for miRNAs dysregulation in cancer. Adapted from [60]. 
 
Importantly, miRNAs affect target genes that are implicated in numerous cellular 
processes involved in cancer development such as proliferation, apoptosis, cell cycle, cell 
adhesion, angiogenesis and inflammation, becoming clear that miRNAs can function either 
as tumor suppressors or oncogenes (oncomiRs) depending on the functions of their target 
genes [59,61,62]. OncomiRs are known to downregulate tumor suppressor genes, and have 
been reported to be overexpressed in multiple miRNA-profiling studies [63]. On the other 
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hand, tumor suppressor miRNAs are responsible for downregulating oncogenes, and are 
mostly underexpressed in cancer [63]. 
Considering the importance of miRNAs in cancer biology, this is a rapidly rising field 
in oncology, since it holds promise for the discovery of new cancer biomarkers and new 
targets for the development of novel cancer therapeutics [64]. 
 
4.1.1. MicroRNAs and HPV-induced Cancers  
Over the past decade, some studies have arisen indicating that miRNAs are possible 
biomarkers of occurrence and development of HPV-induced cancers as well as interactions 
between HPV oncoproteins and miRNAs have also been described [65]. It has also been 
confirmed that HPV is not able to express its own miRNAs, but it disturbs host miRNA 
expression [66]. 
Martinez and colleagues showed that the expression of E6 oncogene reduced the 
miR-218 expression in HPV16 positive cervical carcinomas and that LAMB3 is a possible 
target of miR-218 [67]. Since the LAMB3 protein increases cell migration and promotes 
tumorigenesis in human keratinocytes, the downregulation of miR-218 by E6 and the 
consequent overexpression of LAMB3 may contribute to tumorigenesis [67]. Other study 
from the same group demonstrated that there is a distinctly different miRNA profile in HPV-
associated squamous cell carcinoma of the head and neck (SCCHN) cell lines when 
compared with HPV-negative SCCHN and normal oral keratinocytes cell lines [68]. They 
show that the expression of E6 may result in upregulation of miR-363 and downregulation 
of miR-181a, miR-218 and miR-29a [68].  
The experiments performed by Lajer and co-workers also showed that HPV positive 
SCCHN have a distinct miRNA profile compared with HPV negative SCCHN and that the 
miRNA profile of HPV positive SCCHN and HPV positive cervical squamous cell carcinoma 
(CSSC) are significantly more alike compared with HPV negative SCCHN and CSSC [69]. 
Moreover, this group also identified a set of HPV core miRNAs such as miR-15a, miR-16, 
miR-143, miR-145 and the miR-106-363 cluster [69]. 
A study developed by Greco and colleagues showed that HPV16 E5 protein 
modulates the expression of miRNAs in human epithelial HaCaT cell lines and it seems to 
favor increased cell proliferation and tumorigenesis and, on the other hand, to repress 
epithelial differentiation [70]. 
Consequently, the study and identification of miRNAs associated with HPV-induced 
cancers are essential since they may be useful HPV-specific tumor biomarkers and they 
may prove useful in the development of future individualized treatment strategies and new 
targeted therapies [69]. 
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4.2. MicroRNA-150 
MiR-150 was first identified by its crucial regulatory role in normal hematopoiesis, 
but recent studies have shown that the dysregulation of miR-150 is frequently present not 
only in various types of hematological malignancies, but also in a variety of solid tumors 
[71,72]. 
Interestingly, depending on the genes that miR-150 target, it can act as an oncomiR 
or a tumor suppressor in both malignant hematopoiesis and solid tumors [71,72]. MiR-150 
has been found to be upregulated in myelodysplastic syndrome, chronic lymphocytic 
leukemia, gastric cancer, breast cancer, non-small cell lung cancer and cervical cancer 
[71,72]. On the other hand, miR-150 is downregulated in chronic myeloid leukemia, acute 
myeloid leukemia, mantle cell lymphoma, conjunctival mucosa-associated lymphoid tissue 
lymphoma, Burkitt lymphoma, NK/T-cell lymphoma, pancreatic cancer, esophageal 
squamous cell carcinoma, colorectal cancer and liver cancer [71,72]. In these cancers miR-
150 has multiple targets that are involved in cell differentiation, cell cycle, proliferation, 
apoptosis, invasion and metastasis [71,72].  
Curiously, the transcriptional regulation of miR-150 in HeLa cells seems to be made 
by p53, which is the main target of HPV E6 oncoprotein, and Nuclear factor-kappa B (NF-
kB) p65/RelA [73]. However, the expression profile of miR-150 in HPV-induced lesions 
remains elusive.   
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5. K14-HPV16 Transgenic Mice 
K14-HPV16 transgenic mice Mus musculus are a useful experimental model to the 
study of epigenetic and genetic factors in HPV-induced carcinogenesis, due to the 
morphological and molecular similarities between these mice and humans [64].  
These mice are characterized for having the early-region genes of HPV16 under 
control of the promoter of keratin-14 (K14) with the purpose of directing the early genes 
expression to basal keratinocytes, since this epidermal layer is characterized by expressing 
several keratins such as K14 [74,75]. There are several reports of HPV-induced malignancy 
in transgenic mice with E6 and E7 oncogenes, but these models did not targeted the 
oncogenes expression for keratinocytes, causing neoplastic phenotypes that are dissimilar 
to the multistep development of squamous epithelial neoplasia seen in clinical HPV disease 
[75].  
There are some inbred backgrounds of K14-HPV16 mice, namely C57BL/6, BALB/c, 
SSIN/SENCAR and FVB/n [74]. All of these backgrounds develop hyperplastic and/or 
dysplastic lesions, but only in mice with the background FVB/n there is a progress to 
squamous cell carcinomas, which highlights the key role of host factors in the development 
of HPV-associated tumors [64,74]. Squamous cell carcinomas are observed on epidermis 
of the ear, chest and truncal skin in 21% of FVB/n mice aged 8 to 12 months [64].  
Interestingly, this mouse model recapitulates multi-step carcinogenesis of the human 
uterine cervix [64]. In fact, a study made by Smith-McCune and co-workers have 
demonstrated that lesions from both K14-HPV16 and human cervix are histologically similar 
[76]. The hyperplastic murine lesions are histologically analogous to human cervical 
intraepithelial neoplasia (CIN) I lesions (mild dysplasia) and the dysplastic murine lesions 
are similar to human CIN III lesions (severe dysplasia to CIS) [76,77]. Murine and human 
invasive squamous carcinomas were both composed of clusters of malignant epithelial cells 
surrounded by fibrovascular stroma [76]. In the same study was also compared the patterns 
of angiogenesis by immunohistochemical staining [76]. The results obtained showed an 
upregulation of angiogenesis during the early stages of carcinogenesis in both species [76]. 
The high-grade premalignant lesions and neoplastic lesions in both humans and K14-
HPV16 mice were characterized by an increment in the number of new capillaries and close 
apposition of the microvasculature to the overlying neoplastic epithelium [76]. In both 
species, the expression of the vascular endothelial growth factor (VEGF) was progressively 
upregulated during carcinogenesis [76]. The results of this study demonstrate similarities 
between carcinogenesis and neovascularization in the human cervix and the epidermis of 
K14-HPV16 mice, highlighting the significance of this model to better understand the 
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different players involved in the different steps of cancer progression and to determine how 
to target them for therapeutic applications [76]. 
Given the capacity of this model to reproduce the different stages of carcinogenesis, 
it was chosen in order to study the expression profile of miR-150 in HPV-induced lesions. 
In fact, other miRNAs namely miR-21 and miR-155 were already studied in lesions of these 
mice by Paiva and co-workers [64,78]. These studies concluded that miR-21 expression 
was lower in CIS (ear skin) samples compared with hyperplasia (chest skin) suggesting that 
tissues with lower miR-21 expression are more predisposed to cancer progression [64]. 
Moreover, miR-155 expression was lower in hyperplastic chest skin than in normal chest 
skin suggesting a possible anti-oncogenic effect of miR-155 [78]. 
 Recently, Santos et al. studied the infiltration of CD8+T lymphocytes in HPV-induced 
lesions in this model and demonstrated that celecoxib was able to promote the activation of 
these immune cells [79]. However, the mechanism behind this activation remained unclear 
[79].  
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6. Celecoxib 
The pharmacological agent celecoxib is a specific inhibitor of the cyclooxygenase-2 
(COX-2) that belongs to the class of nonsteroidal anti-inflammatory drugs [80].  
  COX is an enzyme which converts arachidonic acid to cyclic endoperoxidases which 
are then converted to prostaglandins I2, D2 and E2 and thromboxane via their respective 
synthases [81]. COX-2 is the inducible isoform of COX and during inflammation its 
expression is increased [82].  
The anti-inflammatory proprieties of celecoxib are exerted by inhibiting COX-2 and 
consequently inhibiting the synthesis of prostaglandins which play a key role in the 
generation of the inflammatory response [83,84]. 
Celecoxib is approved by the Food and Drug Administration (FDA) for the treatment 
of several diseases including rheumatoid arthritis, osteoarthritis and more recently for the 
reduction of the number of adenomatous colorectal polyps in patients with familial 
adenomatous polyposis, which is a dominantly inherited syndrome of colorectal cancer 
predisposition [80,85,86].  
Investigations have shown that celecoxib has an anti-tumor activity and a 
chemopreventive effect in a wide variety of tumors such as colorectal, head and neck, 
breast and prostate [87–94].  
In fact, celecoxib interferes with tumor initiation and tumor cell growth in vitro and in 
vivo [95]. It has been confirmed that celecoxib induces cell cycle arrest, inhibits tumor 
growth, suppress tumor neo-angiogenesis and induces apoptotic cell death in tumor cells 
and endothelial cells [95]. Moreover, it increases the sensitivity of tumor cells to 
chemotherapy, radiotherapy, or chemoradiotherapy [95].  
COX-2, the target of celecoxib is upregulated in a variety of human premalignant, 
malignant and metastatic epithelial tumors and is associated with poor prognosis [95]. In 
fact, COX-2 has a pro-inflammatory role which is a critical component of tumor progression 
since many cancers arise from sites of infection, chronic irritation and inflammation [96]. 
Furthermore, COX-2 expression contributes to six hallmarks of cancer (Figure 10) [81].  
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Figure 10 - Contribution of COX-2 for the hallmarks of cancer. Adapted from: [81]. 
 
However, it has been confirmed that celecoxib is able to suppress tumor growth 
without an involvement of COX-2 [95]. Actually, celecoxib has COX-2-independent 
molecular targets such as protein kinase B (Akt), kinase 3-phosphoinositide-dependent 
kinase-1 (PDK-1), CKIs and cyclins as well as the anti-apoptotic proteins surviving Bcl-2 
and Mcl-1 [95]. 
In HPV-induced cancers such as cervical cancer, it is suggested that COX-2 
induction is an early event in carcinogenesis, however it seems that celecoxib is 
independent of COX-2 to induce apoptosis and NF-kB appears to have a key role in 
celecoxib-induced apoptosis [97,98]. Moreover, it seems that celecoxib is able to restore 
p53, a tumor suppressor protein that is inhibited by HPV E6 oncoprotein, and consequently 
inhibit apoptosis [99]. Taking into account this relation between celecoxib, p53, NF-kB and 
HPV, it seems interesting to study if celecoxib can interfere in the miR-150 expression 
profile of HPV-induced lesions.  
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Aims of the Study 
The following aims were set:  
 
1. Main aim  
- To evaluate the expression profile of miR-150 in HPV-induced lesions of K14-
HPV16 transgenic mice  
 
2. Specific aims  
- To evaluate and compare the expression profile of miR-150 in chest skin samples 
of wild-type and K14-HPV16 transgenic mice. 
- To study the expression of miR-150 along the progression of HPV-induced lesions 
in K14-HPV16 transgenic mice. 
- To analyze the effect of celecoxib in the expression profile of miR-150 in K14-
HPV16 transgenic mice. 
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Material and Methods  
1. Mice  
In order to perform this study, a model of K14-HPV16 transgenic mice on a FVB/n 
background was used. Creation of K14-HPV16 transgenic mice has been previously 
reported by Arbeit et al. [75]. These transgenic mice were kindly donated by Dr. Jeffrey 
Arbeit and Dr. Douglas Hanahan, through the USA National Cancer Institute Mouse 
Repository. The animal experiments were approved by the University of Trás-os-Montes 
and Alto Douro ethics committee (10/2013) and the Portuguese Veterinary Directorate 
(0421/000/000/2014). 
Wild-type mice and K14-HPV16 transgenic mice (Figure 11) were maintained and 
bred according with the Portuguese (Portaria 1005/92 dated October the 23rd) and 
European (EU Directive 2010/63/EU) legislation, under controlled conditions of temperature 
(23 ± 2°C), light–dark cycle (12h light / 12h dark) and relative humidity (50 ± 10%). Health 
checks were performed daily and food (4RF21 GLP, Mucedola) and water were provided 
ad libitum. 
All mice were previously genotyped by our group through amplification of HPV E6 
and E2 genes in order to assess HPV integration. 
 
 
 
 
Figure 11 - Female mice. a – Wild-type mouse (HPV-/-); b – K14-HPV16 transgenic 
mouse (HPV+/-) with hyperkeratosis and auricular erythema. 
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2. Experimental Design  
The present work employed archived samples from previous experimental 
protocols, performed for the purposes of a previous MSc thesis [79] and an ongoing PhD 
work. All samples were obtained from female mice ascribed to six experimental groups 
(Table 2). 35 K14-HPV16 transgenic (HPV+/-) and 22 wild-type (HPV-/-) female mice were 
maintained up to 24-26 weeks old and 7 HPV+/- and 7 HPV-/- females were maintained up 
to 28-30 weeks old in order to study different stages of carcinogenesis. 
Table 2 - Experimental groups 
Group Genotype Age Treatment 
1 (n = 22) HPV-/- 24-26 weeks No treatment 
2 (n = 21) HPV+/- 24-26 weeks No treatment 
3 (n = 5) HPV+/- 24-26 weeks 124 mg/kg/day of 
celecoxib 
4 (n = 9) HPV+/- 24-26 weeks 75 mg/kg/day of 
celecoxib 
5 (n = 7) HPV-/- 28-30 weeks No treatment 
6 (n= 7) HPV+/- 28-30 weeks No treatment 
 
Celecoxib (Pfizer®) was administrated orally as previously described by Santos et 
al. [79]. Matched control animals (group 2) were administrated the vehicle. Two different 
doses of celecoxib were given, namely 124 mg/kg/day (defined as the “high” dose) and 75 
mg/kg/day (defined as the “low” dose). 
 
3. Samples Collection  
All mice were sacrificed using sodium pentobarbital followed by intracardiac 
puncture and exsanguination, as indicated by the Federation for Laboratory Animal Science 
Associations. Chest skin samples from each animal were collected into TripleXtractor 
reagent (Grisp®), macerated and kept at −80 °C until miRNA extraction. Matched samples 
were collected for histological analysis. 
 
4. Histological Analysis 
The chest skin samples collected for histological analysis were fixated in 10% 
neutral buffered formalin for 48h. The fixed tissues were then dehydrated through graded 
alcohols and xylene and embedded in paraffin using an automatic STP 120 processor 
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(Micro, Boise, ID). The paraffin blocks were cut into 2 µm thick sections and stained with 
haematoxylin and eosin (H&E) for further evaluation on a light microscope.  
Samples were classified as normal skin, epidermal hyperplasia and epidermal 
dysplasia.  
 
5. MicroRNAs Isolation 
MiRNAs were isolated according to an optimized protocol by our group. 
For miRNAs isolation it was added a chloroform solution (EMSURE®) to our 
samples, which after centrifugation at 12.000 g for 15 min, allows the separation of the RNA 
phase. Then, miRNAs were isolated using the commercial kit GRS microRNA Kit (Grisp®).  
After miRNAs isolation, concentration and purity were measured for each sample 
using the NanoDrop® ND-1000 spectrophotometer. The ratio of absorbance at 260 nm and 
280 nm is used to assess contamination with proteins and the ratio of absorbance at 260 
nm and 230 nm is used to assess presence of contaminants as phenols. 
MiRNA samples were kept at −80ºC until further use. 
 
6. Complementary DNA Synthesis  
 The miRNA samples were then used as templates for complementary DNA (cDNA) 
synthesis using a TaqMan® MicroRNA Reverse Transcription Kit (Applied Biosystems®) and 
sequence-specific stem-loop reverse transcription primers for miR-150 and small nucleolar 
RNA-202 (snoRNA-202) (Figure 12) .  
 The amplification conditions were as follows: 30 min at 15ºC, 52 min at 42ºC and 
finally 10 min at 85ºC.  
cDNA was further used as template for quantitative real-time PCR (qPCR). 
 
 
Figure 12 - Reverse transcription of miRNA samples into cDNA by stem-loop reverse 
transcription primers. Adapted from: [100]. 
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7. Quantitative Real-Time PCR 
The miRNA expression was measured by qPCR using a StepOneTM qPCR Real-
Time PCR machine. The reactions were performed in a 48-well plate.  
For each reaction was added 1X TaqMan® Fast Advanced Master Mix (Applied 
Biosystems®) with 1X probes (TaqMan® microRNA Expression Assays, miR-150: 000473, 
Applied Biosystems® or TaqMan® microRNA Expression Assays, snoRNA-202: 001232, 
Applied Biosystems® ) and cDNA sample making a total volume of 10µl (Figure 13). 
To normalize the results, snoRNA-202 was used as endogenous control. SnoRNA-
202 is one of the recommended endogenous controls for miRNA expression data analysis, 
because it demonstrates the highest abundance and least variability in a wide variety of 
tissues and cell lines in mouse [101]. This endogenous control was also previously tested 
by our group.  
The miRNAs quantification was performed in duplicate and negative controls lacking 
cDNA were included in all reactions. 
The thermal cycling conditions were as follows: 10 min at 95ºC followed by 45 cycles 
of 15 seconds at 95ºC and 1 min at 60ºC.  
Data analysis was made using StepOneTM Sofware v2.2 (Applied Biosystems®) with 
the same baseline and threshold set for each plate, in order to generate threshold cycle (Ct) 
values for miR-150 or snoRNA-202 in each sample. The results were confirmed by two 
independent investigators. 
 
 
 
Figure 13 - qPCR using a cDNA sample, forward primer, reverse primer and a dye-
labeled TaqMan probe. Adapted from: [100]. 
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8. Statistical Analysis 
Statistical analysis was performed using the statistical software SPSS for Windows 
(Version 18.0) (IBM® SPSS®).  
T-Student's test was used in order to evaluate any statistical differences in 
normalized relative expression (−ΔCt) of miR-150 between the different groups. 
Results were considered statistically significant when p values were less than 0.05.  
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Results 
1. Histological Analysis  
Evaluation of the skin samples of HPV-/- mice (negative control) on a light 
microscope, showed that these animals presented normal skin histology at both 24-26 
weeks old and 28-30 weeks old (Figure 14a and Table 3). 
Analyzing skin samples of HPV+/- mice at 24-26 weeks of age it was possible to 
observe epidermal hyperplasia characterized by an increase of epidermal thickness, 
increase of the number of cell layers, presence of papillomatosis, hyperkeratosis and 
inflammation in 100.0% of the animals. Dysplastic lesions were observed in 31.8% of the 
animals (Figure 14b and Table 3). 
 In HPV+/- mice at 28-30 weeks of age it was observed hyperplastic lesions in 50% 
of the animals, and dysplastic lesions characterized by the disorganization of the epidermis, 
presence of papillomatosis, hyperkeratosis, mitotic cells, inflammatory cell infiltrates and an 
increase of neo-vascularization in 100% of the animals (Figure 14c and Table 3).  
In HPV+/- mice treated with 124 mg/kg/day of celecoxib the incidence of epidermal 
dysplasia was not observed, however in HPV+/- mice treated with 75 mg/kg/day of celecoxib, 
it was observed dysplastic lesions in only one mice, which corresponds to 12.5%. In all mice 
treated with the two doses of celecoxib, it was observed epidermal hyperplasia (Table 3). 
 CIS and invasive carcinoma were not observed in our samples. 
 
 
 
Figure 14 - Histological Analysis of mice skin samples, H&E, 100x. a – Wild-type mice 
(HPV-/-) showing normal skin; b – K14-HPV16 transgenic mice (HPV+/-) with epidermal 
hyperplasia; c – HPV+/- mice with epidermal dysplasia 
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Table 3 - Histological classification of mice skin samples 
 
* In one of the cases no tissue was available to histological analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Group Age Treatment Cutaneous lesions incidence (%) 
   Normal Skin Epidermal 
hyperplasia 
Epidermal 
dysplasia 
1 (HPV-/-, n = 22) 24-26 
weeks 
No 
treatment 
22/22 
(100%)  
0/0 (0%) 0/0 (0%) 
2 (HPV+/-, n = 21) 
 
24-26 
weeks 
No 
treatment 
0/0 (0%) 22/22 
(100%)  
7/22 (31.8%) 
3 (HPV+/-, n = 5) 
 
24-26 
weeks 
124 
mg/kg/day 
of celecoxib 
0/0 (0%) 5/5 (100%) 0/0 (0%) 
4 (HPV+/-, n = 9 *) 
 
24-26 
weeks 
75 
mg/kg/day 
of celecoxib 
0/0 (0%) 
 
8/8 (100%) 1/8 (12.5 %) 
5 (HPV-/- ,n = 7) 
 
28-30 
weeks 
No 
treatment 
7/7 (100%) 0/0 (0%) 0/0 (0%) 
6 (HPV+/-, n= 7 *) 
 
28-30 
weeks 
No 
treatment 
0/0 (0%) 3/6 (50%) 6/6 (100%) 
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2. MicroRNA-150 Expression 
2.1. MiR-150 is overexpressed in HPV-induced lesions of HPV+/- mice 
To evaluate the miR-150 expression profile in HPV-induced lesions, miR-150 levels 
were measured by qPCR in HPV-induced chest skin lesions of HPV+/- mice and in chest 
skin of HPV-/- mice. The miR-150 expression levels were significantly increased in lesions 
from HPV+/- mice when compared with normal skin from to HPV-/- mice (p < 0.001) (Figure 
15). 
MiR-150 levels were also compared between chest skin tissue of HPV-/- mice and 
HPV+/- mice at 24-26 weeks of age and HPV-/- and HPV+/- mice at 28-30 weeks of age. The 
results obtained were consistent with the previous ones, showing that miR-150 is 
significantly overexpressed in HPV-induced lesions of HPV+/- mice when compared with 
HPV-/- mice in both 24-26 weeks old and 28-30 weeks old mice (p = 0.024 and p = 0.001, 
respectively) (Figure 16).  
 
 
Figure 15 - Normalized relative expression of miR-150 in chest skin tissue of wild-type 
mice (HPV-/-) and K14-HPV16 transgenic mice (HPV+/-). *** p < 0.001. 
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2.2. MiR-150 expression increases along with the severity of HPV-induced 
lesions 
With the purpose of comprehending if the expression level of miR-150 correlates 
with the progression of the lesions and severity, miR-150 expression in HPV+/- 24-26 weeks 
old and 28-30 weeks old mice was compared. Our data suggest a trend for miR-150 
expression level to be significantly increased in the more advanced lesions of older HPV+/- 
mice compared with earlier lesions from younger mice (p = 0.001) (Figure 16).  
In order to study whether the difference in miRNA expression levels between these 
two groups was in fact due to lesions progression, we studied the expression level of miR-
150 in 24-26 weeks old and 28-30 weeks old HPV-/- mice. There were no statistical 
differences between groups (p = 0.104) (Figure 16).  
 
 
 
 
Figure 16 - Normalized relative expression of miR-150 in chest skin tissue of wild-type 
mice (HPV-/-) at 24-26 and 28-30 weeks old and K14-HPV16 mice (HPV+/-) at 24-26 and 
28-30 weeks old. * p < 0.05 ; ** p < 0.01. 
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2.3. Celecoxib influences the expression profile of miR-150 in HPV-induced 
lesions 
The miR-150 expression profile in untreated HPV+/- mice at 24-26 weeks of age and 
age-matched mice treated with a “high” and “low” dose (124 mg/kg/day and 75 mg/kg/day 
respectively) of celecoxib was studied. The results showed that the high-dose of celecoxib 
significantly decreased the expression of miR-150 in HPV-induced lesions when compared 
with HPV-induced lesions from matched control mice (p < 0.001). No statistical differences 
were observed between HPV+/- mice treated with low-dose of celecoxib and HPV+/- mice 
with no treatment (p = 0.114) (Figure 17). 
 
 
Figure 17 - Normalized relative expression of miR-150 in chest skin lesions of K14-
HPV16 mice (HPV+/-) with no treatment, treated with a low-dose of celecoxib (75 
mg/kg/day) and treated with a high-dose of celecoxib (124 mg/kg/day). *** p < 0.001. 
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Discussion 
Nowadays, high-risk HPV is a firmly established etiological agent of several cancers 
including cervical cancer, anogenital cancer and some head and neck squamous cell 
carcinomas, and has become a major health problem worldwide, particularly in developing 
countries  [102]. Although the persistent HPV infection has long been established as 
necessary, the infection by itself may not be sufficient to induce malignant transformation 
[103]. Therefore, in view of the growing need to understand the various factors involved in 
HPV-induced carcinogenesis, the development of experimental models becomes an 
essential tool. The development of K14-HPV16 transgenic mice allows to identify and study 
genetic and epigenetic factors involved in all the stages of the multistep carcinogenesis 
induced by HPV, with high similarities to the HPV-induced carcinogenesis of human cervix 
[74,76].  
In recent years, there has been a growing interest and investment in oncology, 
notably in identifying and defining molecular biomarkers of risk for cancer development.  
Particularly, the study of miRNAs in tumor biology is an area of rapid growth in cancer 
research since they have been identified as potential prognostic biomarkers and possible 
targets for the development of new therapies [104]. Recent studies have significantly 
enhanced the complexity of HPV-induced carcinogenesis with the discovery of miRNAs as 
important players at regulating a variety of pathways [68,69,105,106]. Since miRNAs 
dysregulation is seen in precancerous lesions, they hold promise as early detection 
biomarkers or even therapeutic targets [107]; however, the number of studies that have 
explored these issues are still scarce and sometimes with conflicting results.   
MiR-150 expression has been found to be dysregulated in a variety of solid cancers 
such as cervical, breast, lung, colorectal, gastric, liver, pancreatic and esophageal cancer, 
however its expression profile in HPV-induced lesions remains elusive [108–116]. In the 
present study, it was observed that miR-150 is significantly overexpressed in HPV-induced 
chest skin hyperplastic and dysplastic lesions of K14-HPV16 transgenic mice (HPV+/-) when 
compared with chest skin tissue of wild-type mice (HPV-/-). Since HPV+/- mice at 28-30 
weeks of age present more aggressive HPV-induced lesions and higher levels of miR-150 
when compared with HPV+/- mice at 24-26 weeks of age, it seems that mir-150 expression 
is associated with the severity of HPV-induced lesions. In our samples, CIS and invasive 
carcinoma were not observed, because these stages are only present in older animals [74]. 
Recent studies have documented the aberrant expression of miR-150 associated with 
cancer development and progression through the regulation of oncogenes or tumor 
suppressor genes [71,72]. In cervical cancer, miR-150 has been shown to be upregulated 
when compared with normal cervical tissues and para-carcinoma tissues [108]. A previous 
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study by Li et al. demonstrates that high levels of miR-150 promote cell growth and survival 
by targeting FOXO4, resulting in a decrease of p27, FASL and BIM mRNA and protein 
levels and in an increase of mRNA and protein levels of cyclin D1 (Figure 18) [108]. This 
study also shows that the stage progression is correlated with an increase of miR-150 
expression [108]. This is in agreement with our data since we verified that miR-150 is 
overexpressed in HPV+/- mice and that the expression level of miR-150 is increased along 
with HPV-induced lesions progression.  
 
The oncogenic proprieties of high-risk HPV are mainly due to the expression of E6 
and E7 oncoproteins which lead to the inactivation of p53 and pRB respectively (Figure 19) 
[37].  A previous study by Ghose et al. in human cervical carcinoma HeLa cells, identified 
p53 as a transcription factor that binds to the upstream sequence of miR-150 regulating its 
expression. In the same study, it is reported that when p53 is knocked down in HeLa cells, 
the expression of miR-150 is significantly increased (Figure 19) [73]. These results also 
support our findings since our mouse model expresses the early-region genes of HPV16, 
including E6 and E7 oncogenes in the basal keratinocytes [74].  
 
 
 
 
 
 
 
 
 
Figure 18 – Schematic illustration of how miR-150 promotes cervical cancer cell 
growth and survival. 
Figure 19 – Hypothetical explanation for miR-150 overexpression in HPV+/- untreated mice. 
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Recently, some studies have reported that miR-150 is highly expressed in other 
carcinomas. In breast cancer, upregulation of miR-150 is correlated with growth and 
proliferation and may play a role in the progression of breast cancers [109]. This study by 
Huang et al. showed that miR-150 inhibitors induce apoptosis in breast cancer cell lines 
while ectopic expression of the miR-150 results in increased cell proliferation [109]. P2X7, 
a receptor that regulates cell growth through mediation of apoptosis, it is also identified as 
a new miR-150 target, since miR-150 levels are inversely correlate with P2X7 in breast 
cancer cell lines and carcinomas, and that the 3′-UTR of P2X7 contains a highly conserved 
miR-150-binding site [109]. In gastric cancer cell lines and tissues, miR-150 overexpression 
seems to promote cell proliferation and growth by targeting the pro-apoptotic gene early 
growth response factor 2 (EGR2) [113]. Furthermore, in lung cancer it is also reported that 
miR-150 is upregulated and represses the SRC kinase signaling inhibitor 1 (SRCIN1) by 
directly recognize its 3’-UTR [111]. Repression of SRCIN1 eventually promoted the 
proliferation and migration of lung adenocarcinoma A549 cells [111]. 
Celecoxib is an anti-inflammatory drug and exerts its function by inhibiting COX-2 
and consequently inhibiting the synthesis of prostaglandins which play a key role in the 
generation of the inflammatory response [80,83,84]. It has been proven that celecoxib has 
an anti-tumor and chemopreventive effect through COX-2 dependent or independent 
mechanisms in a wide variety of tumors such as colorectal, head and neck, breast and 
prostate [87–95]. Regarding our study, it was observed that HPV+/- mice treated with 124 
mg/kg/day of celecoxib, have lower miR-150 expression when compared with not treated 
HPV+/- mice. To the best of our knowledge, this is the first study reporting the influence of 
celecoxib in the downregulation of miR-150. To explain our results, we may consider several 
research lines.  
Firstly, a reported study by Saha et al. indicates that celecoxib induces apoptosis by 
restoring p53 in cervical cancer cells infected with HPV18 [99]. The restoration of p53 by 
celecoxib can be achieved by multiple molecular mechanisms, namely: inhibition of HPV 
E6 oncoprotein which is essential for the stabilization and accumulation of p53; inhibition of 
COX-2 increases the transcription of p53 and prevents the association between COX-2 and 
p53 protein, which allows p53 translocation to the nucleus; and activation of the protein 
kinase ATM and p38MAPK which mediate p53 phosphorylation resulting in a 
transcriptionally active p53 (Figure 20) [99]. The study by Ghose et al. reported that in the 
presence of exogenous p53, miR-150 is significantly downregulated (Figure 20) [73]. 
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Secondly, the study by Ghose et al. also identified NF-kB p65/RelA as a transcription 
factor of miR-150 in human cervical carcinoma HeLa cells [73]. This study also showed that 
the expression levels of miR-150 decreased significantly in HeLa cells treated with 
acetylsalicylic acid (Aspirin®), due to the capacity of aspirin to inhibit NF-kB p65/RelA activity 
(Figure 21) [73]. Furthermore, it is reported that celecoxib also has the capacity of inhibiting 
tumor necrosis factor alpha (TNFα)-induced NF-kB activation in a dose-dependent manner 
(Figure 21) [117]. In fact,  a study by Wang et al. shows that the TNFα-induced NF-kB 
activation upregulates miR-150 expression (Figure 21) [118]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20 - Schematic illustration of the first hypothetical explanation for miR-150 
downregulation in HPV+/- mice treated with celecoxib. 
Figure 21 - Schematic illustration of the second hypothetical explanation for miR-150 
downregulation in HPV+/- mice treated with celecoxib. 
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All these findings together may explain why we verified that miR-150 is 
overexpressed in HPV-induced lesions, and why miR-150 is significantly downregulated in 
HPV+/- mice treated with 124 mg/kg/day of celecoxib. Moreover our results also may give 
some light on the activation of CD8+T lymphocytes by celecoxib in HPV16-induced lesions 
in this model, recently reported by our group, since miR-150 downregulation is essential for 
CD8+T cells activation [79,119,120]. 
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Conclusions and Future Perspectives 
With the present findings, it is possible to conclude that the overexpression of miR-
150 occurs in HPV-induced lesions in this model. Its expression seems to increase along 
with the severity of the lesions, reinforcing the hypothesis that miR-150 may act as an 
oncomiR in HPV-induced lesions. We also show that the expression profile of miR-150 is 
altered in the presence of high-dose (124 mg/kg/day) of celecoxib, indicating that this 
miRNA may be a potential biomarker for celecoxib therapy. The effect of celecoxib seems 
to be dose-dependent.  
However, more studies are needed in order to better comprehend the mechanisms 
involved in miR-150 expression and its role in HPV-induced carcinogenesis. In the future, it 
will be interesting to study the expression profile of miR-150 in HPV-induced malignant 
lesions. It will be also important to study the targets of miR-150 in our HPV+/- samples and 
understand if miR-150 levels are associated with apoptosis or inflammation in HPV-induced 
lesions. 
Moreover, it will be interesting to better comprehend the mechanisms underlying the 
modulation of miR-150 by celecoxib. For that purpose, it would be useful to compare the 
p53 and NF-kB status between non-treated and treated samples. 
The study of the different molecular factors involved in HPV-induced carcinogenesis 
will allow the identification of new targets and consequently the putative development of 
new and more efficient therapies. 
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